Editorial on “The AvaALL Randomized Clinical Trial”

Angiogenesis is essential for tumor growth and blood-borne metastasis, while pharmacological inhibition of tumor-induced angiogenesis is a strategy used in several solid tumors. In advanced non-squamous non-oncogene addicted non-small cell lung cancer (NSCLC), the use of bevacizumab—a monoclonal antibody targeting vascular endothelial growth factor (VEGF)—in addition to platinum-doublet is approved for first-line treatment (1,2).